Baidu
map

Nat Commun:前列腺癌中雄激素受体结合位点高度变异

2020-02-21 AlexYang MedSci原创

雄激素受体(AR)信号几乎在所有类型的前列腺癌中都是必需的。AR介导转录的任何变化能够对致瘤过程和肿瘤生长起到深远的影响。虽然AR蛋白的变异已经有很多的研究,但是关于发生在AR结合DNA的非编码区的体细胞变异了解很少。最近,有研究人员使用临床全基因组测序发现了AR结合位点的变异比例存在大幅增加,并且比其他任何转录因子都要高,并且特异性的存在前列腺癌中。另外,研究人员还发现乳腺癌中雌激素受体结合位点

雄激素受体(AR)信号几乎在所有类型的前列腺癌中都是必需的。AR介导转录的任何变化能够对致瘤过程和肿瘤生长起到深远的影响。虽然AR蛋白的变异已经有很多的研究,但是关于发生在AR结合DNA的非编码区的体细胞变异了解很少。

最近,有研究人员使用临床全基因组测序发现了AR结合位点的变异比例存在大幅增加,并且比其他任何转录因子都要高,并且特异性的存在前列腺癌中。另外,研究人员还发现乳腺癌中雌激素受体结合位点的变异比例也提高,阐释了在谱系特异性转录因子上述情况也许是常见的。研究人员还表明了这些位于AR结合位点的变异以及其他相关的转录因子的变异是由于基础位点的错误修复引起的。

最后,研究人员指出,他们的工作阐释了非编码AR结合位点在前列腺癌中变异频率高,并能够影响增强子活性。

原始出处:

Tun? Morova, Daniel R. McNeill, Nada Lallous et al. Androgen receptor-binding sites are highly mutated in prostate cancer. Nat Commun. 11 Feb 2020

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087661, encodeId=edd2208e66185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 25 05:45:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884131, encodeId=54421884131cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 30 12:45:00 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342656, encodeId=bc18134265628, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040667, encodeId=386c104066e77, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 21 14:45:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-04-25 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087661, encodeId=edd2208e66185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 25 05:45:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884131, encodeId=54421884131cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 30 12:45:00 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342656, encodeId=bc18134265628, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040667, encodeId=386c104066e77, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 21 14:45:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-12-30 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087661, encodeId=edd2208e66185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 25 05:45:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884131, encodeId=54421884131cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 30 12:45:00 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342656, encodeId=bc18134265628, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040667, encodeId=386c104066e77, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 21 14:45:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087661, encodeId=edd2208e66185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 25 05:45:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884131, encodeId=54421884131cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 30 12:45:00 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342656, encodeId=bc18134265628, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040667, encodeId=386c104066e77, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 21 14:45:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087661, encodeId=edd2208e66185, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 25 05:45:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884131, encodeId=54421884131cb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Dec 30 12:45:00 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342656, encodeId=bc18134265628, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350563, encodeId=b4e81350563bd, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 23 02:45:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040667, encodeId=386c104066e77, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 21 14:45:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-21 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Cancer Immunol Immunother:混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究

之前人们开发了一种包含20种混合多肽(KRM-20)的新的癌症疫苗来诱导细胞毒性T淋巴细胞,从而抵抗12种不同的肿瘤相关的抗原。最近,有研究人员在II期试验中调查了是否KRM-20组合多烯紫杉醇和地塞米松能够在去势抵抗性前列腺癌(CRPC)患者中增强抗肿瘤作用。研究是一个双盲、安慰剂对照和随机II期研究,研究人员在日本10个医疗中心招募了无化疗CRPC患者。符合要求的患者以1:1的比例随机分配在K

Cancer Med:前列腺癌恶化过程中ANO5作用分析

Anoctamins最初被鉴定为是钙激活氯离子通道家族之一,但近期的研究表明了它们在不同类型恶性肿瘤发展过程中的作用。最近,有研究人员在10个anoctamin基因中评估了211个常见的单核苷酸多态性与局部前列腺癌根治性切除术(RP)后生化复发(BCR)之间的相关性情况。研究发现,在多次测试校正(P<0.05和q=0.232)和调整了已知的预后因素后,4个SNPs(ANO4 rs585335

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

Trovagene是一家临床阶段的肿瘤治疗公司,其研究性新药Onvansertib预期用于治疗包括前列腺癌、结肠直肠癌和白血病在内的多种癌症,该公司近日宣布,正在进行的Onvansertib与Zytiga联合治疗转移性去势抵抗性前列腺癌(mCRPC)的II期试验取得了积极结果。

Prostate Cancer P D:他汀类药物、预防性护理和前列腺癌死亡率相关性分析

越来越多的证据表明了他汀类药物和前列腺癌特异性死亡率(PCSM)的减少存在相关性。然而,这些研究中可能存在显著的偏差。其中一个特别的评估偏差为健康护理的影响,可通过筛选模式进行量化。最近,有研究人员在一个具有详细纵向信息的数据库中评估了他汀类药物的使用、筛选和PCSM间的相关性。研究群体包括了68432名男性,其中40772名(59.6%)为诊断前他汀类使用者,27660名(40.4%)为非使用者

Prostate:前列腺癌男性患者需求的定量分析

恶性前列腺癌(PCa)男性患者的指南最近有所变化,包括了遗传咨询(GC)和/或遗传测试(GT)。最近,有研究人员鉴定了PCa男性患者在GC之前和从GC中想获得的信息情况。研究的小组中包括了PCa男性患者,研究人员对交流进行了录音,并对与GT相关的主题、他们期望从健康护理者中想获得的信息以及与家庭成员有关的一些信息进行了分析。研究中共有37名PCa男性患者,共有7个焦点小组。研究发现,几乎所有的男性

Sci Rep:牛蒡甙元能够通过对脂肪组织和肿瘤的双重作用来抑制前列腺肿瘤的生长

最近,有研究人员调查了牛蒡甙元-一种新的抗炎症木酚素,在肥胖条件下,体内和体外试验中对前列腺癌的抑制作用情况。研究中,体外肥胖模型通过共培养脂肪细胞3T3-L1与雄激素敏感性LNCaP人类前列腺癌细胞,或者在脂肪细胞条件培养基中培养LNCaP细胞来建立。研究发现,牛蒡甙元能够显著的抑制LNCaP增殖,并减少雄激素受体(AR)和增加Nkx3.1细胞表达。研究人员将人类前列腺癌LAPC-4异种种植肿瘤

Baidu
map
Baidu
map
Baidu
map